Class: Leukotriene receptor antagonist
- Tablets 10 mg
- Tablets 20 mg
Inhibits 3 leukotriene receptor types. Leukotrienes have been associated with the longer, inflammatory component of asthma.
Rapidly absorbed. T max is 3 h. Bioavailability is unknown. Administration with food reduced the mean bioavailability about 40%.
At least 99% bound to proteins (predominantly albumin). Vd is 70 L. Minimal distribution across blood-brain barrier.
Extensively metabolized. Most common metabolic products are hydroxylated metabolites, which are excreted in feces. These metabolites are formed through the CYP-450 2C9 pathway. Inhibits CYP3A4 and CYP2C9 isoenzymes.
Oral Cl is about 20 L/h. Biliary route is primary route of excretion. Urinary excretion accounts for about 10% of the dose, while the rest is excreted in feces. The terminal t ½ is about 10 h. The plasma t ½ is about 8 to 16 h.
Special PopulationsHepatic Function Impairment
Approximately 50% to 60% greater C max and AUC compared with healthy subjects.Elderly
Oral Cl decreases with age. In patients older than 65 yr of age, there are about 2- to 3-fold greater C max and AUC compared with young adults.
Indications and Usage
Prophylaxis and chronic treatment of asthma in adults and children 5 yr of age and older.
Dosage and AdministrationAdults and Children 12 yr of age or older
PO 20 mg twice daily.Children 5 to 11 yr of age
PO 10 mg twice daily.
- Not to be used for the acute treatment of bronchospasm or asthma symptoms.
- May be used alone or in combination with bronchodilators and inhaled or systemic corticosteroids.
- Administer prescribed dose 1 h before or 2 h after meals.
Store tablets at controlled room temperature (68° to 77°F). Protect from light and moisture.
Increased zafirlukast plasma levels.Erythromycin, theophylline
Lowered zafirlukast plasma concentrations.Warfarin
Zafirlukast potentiates the hypoprothrombinemic effect of warfarin. Significant increase in the PT may result.
Laboratory Test Interactions
None well documented.
Headache (13%); dizziness (2%).
Nausea, diarrhea (3%); vomiting (2%); dyspepsia (1%).
ALT elevations (2%).
Hypersensitivity (including urticaria, angioedema, rashes).
Infection (4%); pain, asthenia, abdominal pain, accidental injury, fever, back pain (2%).
Category B .
Excreted in breast milk.
Safety and efficacy in children younger than 5 yr of age not established.
Drug Cl decreases with age.
Zafirlukast is not effective in treating acute asthmatic symptoms, but it can be continued during these times.
Elderly patients experienced an increased frequency of infections (primarily respiratory) compared with placebo-treated patients. These appeared to be associated with coadministration of inhaled corticosteroids.
Rash, upset stomach.
- Advise patient to take each dose on an empty stomach, either 1 h before or 2 h after meals.
- Advise patient to continue taking other medications for asthma as prescribed by health care provider.
- Warn patient that drug is an asthma controller and is not to be used to treat an acute asthma attack. Advise patient to continue to take zafirlukast during an acute attack but to use rescue medication (bronchodilator) to obtain rapid relief of asthma symptoms.
- Instruct patient not to stop the medication once symptoms have been controlled. Continued daily use is necessary to control symptoms.
- Advise patient not to change the dose or stop using unless advised by health care provider.
- Instruct patient not to exceed prescribed dose. Advise patient to contact health care provider if this medication no longer seems to control asthma symptoms.
- Advise patient to discontinue therapy and contact health care provider immediately if any of the following occur: persistent nausea; unexplained fatigue; excessive sleepiness or drowsiness; stomach pain; flu-like symptoms; itching; yellowing of skin or eyes; appetite loss.
- Advise patient to carry medical identification (eg, card, bracelet) indicating asthma.
Copyright © 2009 Wolters Kluwer Health.